Main Content
Systems Biology of Lung Inflammation
Aiming at a personalized medicine for patients with lung disease, we analyze the multitude of clinical and experimental data, as well as the complexity of human diseases by means of high throughput screening, bioinformatics, and mathematical modelling.
Systems Biology Platform - German Centre for Lung Research (DZL)
The Systems Biology Platform integrates clinical and patient data with high throughput "-omics" data to develop new in silico models of lung inflammation in pneumonia, asthma and COPD, thereby complementing the "Deep Phenotyping" approach of the German Centre for Lung Research.
Website of the German Centre for Lung Research
CAPSyS - Systemmedizin der ambulant erworbenen Pneumonie
BMBF e:med: Maßnahmen zur Etablierung der Systemmedizin
e:Med is a new large-scale research program on Systems Medicine, funded by the Federal Ministry of Education and Research (BMBF) for 8 years.
e:Med brings together leading scientists and exceptional young researchers from all over Germany in the emerging field of Systems Medicine. Systems medicine uses interdisciplinary systems-oriented research on diseases to create a basis for understanding complex physiological and pathological processes for development of innovative personalized diagnosis, therapies, and preventive measures. Key to the appropriate analysis and possibly to the modelling of Big Data derived from information levels such as Genomics, Proteomics and Metabolomics is electronic processing (e:Med) i.e. computerized archiving, analysis and integration of data.
TP04: Experimental modelling and validation of pneumonia pathophysiology
In this subproject, central aspects of pneumonia pathology inaccessible to patient-centered research will be elucidated in highly standardized and well-controlled experimental models in vitro, ex vivo and in vivo to provide homogenous data as starting points for mathematical modeling of pathophysiologic sequences. The experimental models will be designed to parallel the patient’s course of disease or specific aspects thereof. Further experiments will be hypothesis-driven and focus on promising signaling pathways and specific pathogen and host factors. With increasing progress of the mathematical modeling, the project is aimed at tightly interacting iteratively with the mathematical modelers to answer their questions regarding specific pathophysiological sequences of pneumonia that are considered particularly relevant or remain unclear.
Collaboration Partner: Prof. Dr. med. Martin Witzenrath, Charité - Universitätsmedizin Berlin
JPI-AMR - Joint programming initiative on antimicrobial resistance
BMBF / ERACoSysMed
Project: Prevention and Restriction of Antimicrobial Resistance in Pneumococci by Multi-Level Modelling (Restrict-Pneumo-AMR)
This project aims to understand the mechanisms and distribution of this pneumococcal AMR repertoire at the genetic, bacterial, host and population levels to layout new strategies for risk assessment, prevention and reduction of AMR. In particular, the environmental, immunological and pharmacological drivers of resistance emergence and selection, the genetic population dynamics, as well as the fitness of the new traits in different host conditions will be analysed and modelled.
Cooperation partners:
Bentley, Stephen Bentley, Wellcome Trust Sanger Institute, UK
Nahuel Fittipaldi, University of Toronto, Canada
James Kellner, University of Calgary, Canada
Paul Turner, University of Oxford, UK
Tom van der Poll, University of Amsterdam, Netherlands